ERBB2 and neoplasm: To investigate if the internalization profile of SORT1 would provide SORT1-targeted ADCs with a more powerful anti-tumor effect, we compared the cell cytotoxicity between SORT1-targeted ADCs and HER2-targeted ADCs using 8D302-DXd and trastuzumab-DXd, a biosimilar of DS-8201a.